-Former DAVIDs TEA COO & Starbucks SVP International Operations-
BOSTON--(BUSINESS WIRE)--Sep. 9, 2015--
to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is
developing innovative and proprietary treatments for exercise-associated
muscle cramps, nocturnal leg cramps, and spasms associated with severe
neuromuscular conditions, today announced the appointment of Kathie
Lindemann as its Chief Operating Officer, reporting to Christoph
Westphal M.D., Ph.D., Flex Pharma’s President, CEO and Chair.
Prior to joining Flex Pharma, Ms. Lindemann served as Chief Operating
Officer at DAVIDs TEA Inc. Ms. Lindemann also spent 19 years at
Starbucks where she held several leadership roles including Senior Vice
President, Starbucks Foodservice, SVP US Business Operations, and SVP
International Operations, Store Development and Global Business Systems.
She has been a Director of Cambia Health Solutions, Inc. since June
2009. She is a graduate of the University of Santa Clara.
“Since we see substantial opportunity to develop our consumer product as
a global brand, I am looking forward to working with Kathie to leverage
her extensive experience building and running operations ex-US as we
plan to access key international markets,” commented Marina Hahn,
President of Consumer.
“Flex Pharma has built a premier team of consumer brand talent with a
proven track record, led by President of Consumer, Ms. Hahn,” noted Flex
Pharma Board member John Sculley, former Apple CEO and PepsiCo CEO. “The
addition of Ms. Lindemann strengthens Flex Pharma’s capabilities to
launch a global brand.”
“Our ability to attract high caliber talent from both biotech and
consumer backgrounds is a testament to the strength of Flex Pharma’s
unique profile and exciting growth potential,” said Christoph Westphal,
M.D., Ph.D., Chairman and Chief Executive Officer of Flex Pharma.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for exercise-associated muscle
cramps, nocturnal leg cramps, and spasms associated with severe
neuromuscular conditions. In three randomized, blinded,
placebo-controlled, cross-over studies, Flex Pharma's proprietary
treatment has shown a statistically significant reduction in the
intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Individuals can follow the Company on twitter (@flexpharma) and the
Company's website (http://ir.flex-pharma.com/)
to see the latest progress of the Company's pre-launch activities for
its consumer product to prevent and treat exercise-associated muscle
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: including our plans to expand to
international markets; and the timing of and our expectations for the
launch of our consumer product. Various factors may cause differences
between our expectations and actual results as discussed in greater
detail under the heading “Risk Factors” in our Annual Report on Form
10-K for the year ended December 31, 2014 and subsequent filings with
the Securities and Exchange Commission (SEC). You are encouraged to read
Flex Pharma’s filings with the SEC, available at www.sec.gov,
for a discussion of these and other risks and uncertainties. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150909005318/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications